203866-21-1

Basic information

• Product Name: (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid
• Synonyms: (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid;FMoc-4,4-difluoro-L-Pro-OH;(2S)-1-Fmoc-4,4-difluoropyrrolidine-2-carboxylic acid;(2S)-FMOC-4,4-difluoro-pyrrolidine-2-carboxilic acid;Fmoc-L-4,4-difluoroproline;1-Fmoc-4,4-difluoro-L-proline
• CAS NO: 203866-21-1
• Molecular Formula: C20H17 F2 N O4
• Molecular Weight: 373.35
• Mol File: 203866-21-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 550.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 3.00±0.40(Predicted)
• CAS DataBase Reference: (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid(203866-21-1)
• EPA Substance Registry System: (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid(203866-21-1)

Safety Data

• Hazardous Substances Data: 203866-21-1(Hazardous Substances Data)

Usage

General Description

"(2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid" is a chemical compound with a molecular formula C18H19F2NO4. It is a derivative of pyrrolidine-2-carboxylic acid and contains a fluorine substitution at the 4th position of the pyrrolidine ring. The compound is often used as a building block in the synthesis of peptide and protein-based pharmaceuticals. It is also commonly used in solid-phase peptide synthesis due to its ability to protect the amine group in the peptide chain. Additionally, the Fmoc (9-fluorenylmethyloxycarbonyl) protecting group allows for selective deprotection under mild conditions, making it a versatile tool in peptide chemistry. Overall, "(2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid" is an important chemical compound in the field of medicinal and pharmaceutical research.

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 497-19-8 sodium carbonate 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 52683-81-5 (S)-4,4-difluoro-pyrrolidine-2-carboxylic acid 

Downstream Products

• 1609430-63-8 (S)-1-((S)-1-(4-(benzyloxy)-3-fluorobenzoyl)-4,4-difluoropyrrolidine-2-carbonyl) pyrrolidine-2-carbonitrile 
• 1440522-02-0 C₃₉H₆₄F₂N₁₂O₈ 

Relevant articles and documents

Inhibitors of caspases

The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1β converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), or interferon-γ-(“IFN-γ”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-γ production and methods for treating interleukin-1, apoptosis-, and interferon-γ-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.